First-in-human study explores a single injection that provides 3 months of protection
- This is the first clinical trial for Quotient Sciences and Medicines for Malaria Venture (MMV) of MMV371, a long-acting injectable.
- The injectable could offer up to 3 months of protection against all types of malaria.
- If successful in clinical trials, the final product has the potential to be a game changer, offering an affordable, long-lasting option to protect people of all ages from malaria.
- The trial is being administered at Quotient Sciences – Nottingham, UK clinic in healthy male and female volunteers.
Nottingham, United Kingdom and Geneva, Switzerland — 28 October 2024. Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first clinical trial for a long-acting injectable (LAI) preventive compound for malaria. The trial, conducted in healthy volunteers in Nottingham, UK, marks a significant step toward preventing malaria in endemic regions.
According to the World Health Organization, in 2022, there were 249 million malaria cases and 608,000 deaths globally with sub-Saharan Africa bearing 95% of this burden. Innovations in malaria prevention are essential to respond to this ongoing public health crisis. In this trial, MMV371, a derivative of atovaquone — already approved as part of atovaquone-proguanil (Malarone®), a medicine widely used by travellers to malaria-endemic areas — is being tested in an injectable form that could provide up to 3 months of protection with a single intramuscular dose.
First-in-human clinical trial
The trial is evaluating the drug’s safety, tolerability and pharmacokinetics, or how the body interacts with the medicine. The final injectable medicine will be a fixed-dose combination of MMV371 and a suitable partner drug — a strategy that reduces the likelihood of inducing resistant strains of malaria parasites. Another compound in MMV’s pipeline, MMV055, is a potential partner drug candidate and is expected to enter clinical development in 2025.
The study is evaluating different dose levels of MMV371 in adult volunteers. If approved, this new product could potentially play a key role in protecting against new infections from all malaria parasite species, including the two most common strains, Plasmodium vivax and Plasmodium falciparum, the most deadly form of malaria.
An innovative approach to malaria prevention
The new drug combination could also potentially clear asymptomatic malaria infections, a condition in which malaria parasites are present in the blood, but no symptoms appear. Addressing asymptomatic malaria is an important element of malaria elimination strategies as individuals who are infected but have no disease symptoms are unlikely to seek treatment, therefore contributing to ongoing disease transmission. Over time, this unchecked transmission can lead to the emergence and spread of drug-resistant malaria as the parasite is continuously exposed to various antimalarial drugs used in symptomatic individuals.
Pending positive outcomes of the study, clinical trials in malaria-endemic countries are expected to begin in 2026. The final product could be a vital tool suitable for broad populations and multiple malaria strains, with the potential to complement existing interventions such as vaccines; seasonal malaria chemoprevention (SMC), a highly effective preventive oral intervention administered mainly to children under 5; and ideally, intermittent preventive treatment of malaria in pregnancy. An LAI could be advantageous in regions where SMC campaigns cannot be deployed due to parasite resistance to the drugs currently used. “This trial brings us closer to our goal of offering a long-lasting, affordable solution for malaria prevention”, said Dr Stephan Chalon, Vice President of Experimental Medicine and Clinical Pharmacology at MMV.
Dr Nand Singh, Medical Director at Quotient Sciences, said “We are pleased to support MMV with the clinical development of the antimalarial drug MMV371. The potential to help protect against P. vivax and P. falciparum strains and help save human lives is something that we are proud to be part of. This project will provide the scientific evidence for the potential development of long-acting injectable anti-malarial treatment.”
Affordability and broad reach
With affordability a key requirement of its target product profile, the LAI is intended for all age groups, especially young and school-aged children, who are among the highest risk for malaria infection and death. The LAI’s affordability, single-dose administration and ability to prevent malaria cases and treat asymptomatic infections make it a potential game-changer for global malaria elimination efforts.
About MMV
MMV is a Swiss-based not-for-profit organization working to deliver a portfolio of accessible medicines with the power to treat, prevent and eliminate malaria. Born in 1999, out of a need for greater health equity, we close critical gaps in research, development and access — working “end-to-end” to expand the use of existing antimalarials and innovate new compounds to protect public health. This starts with women and children.
It’s working. As of 2023, MMV-supported products have effectively protected or treated an estimated 680 million people and saved around 15.4 million lives. We cannot stop now.
However, with a quarter of a billion malaria cases and more than 600,000 deaths reported in 2022, progress towards disease elimination has stalled. MMV is part of an ecosystem of partners determined to change this. Bringing public and private sector partners together, we pioneer new solutions that align with local and global health priorities and promote the equitable development of effective and affordable products that work to help end malaria and advance health for all. For more information, visit www.mmv.org.
For press enquiries, contact:
Doreen Akiyo Yomoah
Communications Manager, MMV
Phone +41 79 238 60 74
E-mail: yomoahd@mmv.org
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programmes and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast, because humanity needs novel therapeutic solutions, fast. Quotient Sciences has been recognized as a multi-year winner of the CRO Leadership Awards in 2021, 2022, and 2024 and of the CDMO Leadership Awards in 2023. For more information, visit quotientsciences.com.
For press enquiries, contact:
Erica Fearnley
Executive Director, Strategic Marketing at Quotient Sciences
erica.fearnley@quotientsciences.com
Rachael Heath
Senior PR Manager at RaMarketing & PR
rachael@ramarketingpr.com
MMV Disclaimer
This document contains certain forward-looking statements that may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions, or by discussion of, among other things, vision, strategy, goals, plans, or intentions. It contains hypothetical future product target profiles, development timelines and approval/launch dates, positioning statements, claims and actions for which the relevant data may still have to be established. Stated or implied strategies and action items may be implemented only upon receipt of approvals including, but not limited to, local institutional review board approvals, local regulatory approvals, and following local laws and regulations. Thus, actual results, performances or events may differ from those expressed or implied by such statements. We ask you not rely unduly on these statements. Such forward-looking statements reflect the current views of Medicines for Malaria Venture (MMV) and its partner(s) regarding future events, and involve known and unknown risks and uncertainties. MMV accepts no liability for the information presented here, nor for the consequences of any actions taken on the basis of this information. Furthermore, MMV accepts no liability for the decisions made by its pharmaceutical partner(s), the impact of any of their decisions, their earnings and their financial status.